Mauro Ferrari - 26 Dec 2025 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Director
Signature
/s/Mauro Ferrari
Issuer symbol
ARWR
Transactions as of
26 Dec 2025
Net transactions value
-$527,100
Form type
4
Filing time
30 Dec 2025, 17:46:28 UTC
Previous filing
18 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ferrari Mauro Director 177 E. COLORADO BLVD, SUITE 700, PASADENA /s/Mauro Ferrari 30 Dec 2025 0001506045

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale $527,100 -7,530 -9.8% $70.00 69,053 26 Dec 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.